Standard BioTools Announces Appointment of Fenel Eloi to Board of Directors
15 mars 2023 08h30 HE
|
Standard BioTools Inc.
SOUTH SAN FRANCISCO, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today...
Standard BioTools to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum
14 mars 2023 08h30 HE
|
Standard BioTools Inc.
SOUTH SAN FRANCISCO, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today...
Standard BioTools to Present at 43rd Annual Cowen Health Care Conference
01 mars 2023 16h05 HE
|
Standard BioTools Inc.
SOUTH SAN FRANCISCO, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today...
Standard BioTools Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
21 févr. 2023 08h30 HE
|
Standard BioTools Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB) today announced that the Compensation Committee of its Board of Directors, which is composed...
Standard BioTools Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Business Outlook
14 févr. 2023 16h05 HE
|
Standard BioTools Inc.
Fourth quarter 2022 GAAP revenues of $27.0 million; Core product and service revenues of $26.8 million, representing 8.3% sequential growth; Full year GAAP revenues of $97.9 million and core product...
Standard BioTools Announces Conference Call and Webcast for Fourth Quarter and Full Year 2022 Financial Results
31 janv. 2023 08h30 HE
|
Standard BioTools Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today...
Standard BioTools Provides Preliminary Fourth Quarter 2022 Revenue and Business Update
09 janv. 2023 08h30 HE
|
Standard BioTools Inc.
Continued commercial and strategic execution delivers sequential core revenue growth of 4%–9% to $26 million–$27 million in Q4 2022 for full year total of approximately $94 million–$95 million ...
Standard BioTools Announces Appointment of Betsy Jensen as Chief Human Resources Officer
03 janv. 2023 08h30 HE
|
Standard BioTools Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today...
Standard BioTools Authorizes up to $20 Million of Share Repurchases
28 nov. 2022 08h30 HE
|
Standard BioTools Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – unleashing tools to accelerate breakthroughs in human health – today...
Standard BioTools Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
22 nov. 2022 09h20 HE
|
Standard BioTools Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB) today announced that the Compensation Committee of its Board of Directors, which is composed...